Advertisement
Advertisement

More Related Content

Advertisement

More from ILRI(20)

Advertisement

Towards a vaccine for African swine fever

  1. Lucilla Steinaa, Principal Scientist, ILRI International Symposium on Animal Functional Genomics & Health 19 Nov 2020 Towards a vaccine for African swine fever
  2. • Caused by a large double stranded DNA virus. • Between 150-167 genes, 22 genotypes based on the p72 sequence. • Belongs to the family Asfaviridae, nearest relatives are the poxviruses. • There is a wildlife reservoir : warthogs, bush pigs. Soft ticks are involved in transmission. African swine fever
  3. • ASF is now a huge problem in Eastern Europe, Russia, China, Asia, and Africa. • ASF is present in about 26 countries in Africa. Multiple genotypes are present. • ASF is a major problem for potential pig farmers, who are discouraged from entering the pig business due to ASF. African swine fever
  4. The architecture of the virus Wang et al. 2019
  5. Neighbor-Joining tree depicting the p72 gene relationships and geographical distribution of the major ASFV genotypes CAM/1/02 CAM/4/85 GHA/1/02 LIS/60 NIG/1/01 ANG/70 IC/2/96 BEN/1/97 SPEC/205 SPEC/209 Mkuzi/79 I MOZ/1/02 MOZ/1/05 LUS1/93 MOZ/2/02 MOZ/1/03 II RSA/5/95 SPEC/257 RSA/3/03 RSA/Warmbaths III MOZ/1979 MAL/1/02 MOZ/1960 Tengani/62 V MOZ/8/94 SPEC265 MOZ/1/94 VI RSA/3/04/ RSA/Warthog RSA/1/99/W IV RSA/2/96 RSA/2/03 RSA/3/96 RSA/1/04 XIX Lillie RSA/1/95 XX XIIIRSA/1/03 RSA/4/95 RSA/1/98 SPEC/154 VII XIVNYA/12 TAN/2/03 TAN/1/03 XVI XVTAN/1/01 XIIISUM/14/11 XIIMZI/1/92 XIKAB/6/2 MCH/1/89 MCH/3/89 BAN/1/91 DED/1/89 LIL/20/2 DOWA CHJ/1/89 KLI/2/88 PHW/1/88 TMB/1/89 VIII UGA/1/95 KEN/5/01 IX BUR/1/84 BUR/1/90 Kenya/50 X 100 79 74 57 91 0.005 p72 gene Contribution: Livio Heath (ARC-OVI) Distribution of genotypes in Africa Genotype I Genotype II,III, IV, V, VI, VII, XIX, XX, XIII Genotype VIII, XI, XII, XIII, XV, XVI, XIV Genotype IX, X
  6. Engineering of African Swine Fever Virus for Production of Live Attenuated Vaccine Candidates
  7. Engineering of African Swine Fever Virus for Production of Live Attenuated Vaccine Candidates • Establishment of vaccine platforms for making attenuated African swine fever vaccine candidates • Gene modification by CRISPR-Cas. • Gene modification by using a synthetic approach – reverse genetics system • International Livestock Research Institute, J. Craig Venter Institute and Friedrich Loeffler Institute.
  8. • The virus • Genotype IX isolated from an outbreak area between Uganda and Kenya. Genomic sequence available. • Viruses from current outbreak areas in the region (Kenya, Uganda, (Tanzania)) have been sequenced at ILRI. All are genotype IX and X, and genomes are almost identical to the one we have. Genotype IX and X have been detected in outbreaks in Congo. Virus backbone for modification of ASFV Gallardo C et al. A.J. Biotech 2011 Onzere C. et al. Virus Genes 2018
  9. CRISPR approaches for gene modification
  10. CRISPR-modification pathway (NHEJ) Stable CAS transfected cell line (WSL) Transfection with guide RNA Infect with GFPvirus Harvestsup./cells with virus 10-1 10-2 10-3 10-4 10-5 10-6 Checkfor genome modifications Dilutions Virusclones Genome cleavage detection kit OR DNA Sequencing of modified region
  11. Genome cleavage detection uncleaved cleaved Mismatched heterogenous duplex Denature & Reanneal GeneArt™GenomicCleavageDetection Kit Digestw/ detection enzyme Cleaved heteroduplex Electrophoresis T C T-Treated C- Control PCRamplify targeted locus Banddensitometryfor cleavageefficiency G1 G2 C 1 2 3 500 PCRamplify targetedlocus 1 2 3 Denature& Reanneal Digest w/ detectionenzyme Electrophoresis CRISP-modification of two genes (SingleguideRNA) 500 300 200 1 2 3 1 2 3 negative enzyme control
  12. Clones tested with genome cleavage kit PCR amplify targeted locus (500bp) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 W 15 16 17 18 19 20 21 22 23 24 25 26 28 29 W27 Spike with wildtype DNA amplicon: Denature & Reanneal and Digest w/ detection enzyme 1 2 3 4 5 6 7 8 9 10 11 12 13 14 W15 16 17 18 19 20 21 22 23 24 25 26 28 29 W27 Assorted clones: Denature & Reanneal and Digest w/ detection enzyme 2 3 9 10 11 12 16 19 21 25 29 W23 Sequence clones 2, 3, 9, 11, 12, 16, 19, 29… 25 and wt to confirm editing
  13. A clone virus with desired mutation 1 2 3 1 2 3 gRNA target Stop Codon
  14. 17th Oct 2019 Reflections on the NHEJ pathway • Bias towards in-frame indels using NHEJ, one guide RNA approach. • Difficulties in cloning due to lack of marker for modification. Mitigation: • Use HDR approach NHEJ pathway
  15. Homology directed repair pathway ASFV gene RHALHA LHA RHA Plasmid GFP in ASF genome ASF genome
  16. GFP plasmid pGFPΔA238L for integration of GFP in the ASF genome 17th Oct 2019 pGFPΔA238L, synthesised by GenScript circular linear Infection /transfection experiments in WSL– Cas cell line Kenya 1033 (WT) + plasmid Kenya 1033 (WT) + amplicon Kenya 1033 (∆CD2v) + plasmid Kenya 1033 (∆CD2v) + amplicon
  17. Microscopy after transfection of pGFPΔA238L in Kenya1033-ΔCD2v-DsRed Super-imposed images DsRed eGFP Two
  18. PCR confirmation of GFP genome integration 17th Oct 2019 Amplicon sizes: F1R1 (5′) = 1488 bp F1R2 = 3740 bp (KO), F1R2 = 3337 bp (wt), F2R2 (3′) = 1681 bp Expected band sizes for both amplicon and plasmid transfections in Kenya1033 & Kenya1033-ΔCD2v Kenya1033 amplicon Kenya1033 plasmid 1033-ΔCD2v plasmid 1033-ΔCD2v amplicon F1R1 F2R2 F1R2 F1R1 F2R2 F1R2 F1R1 F2R2 F1R2 F1R1 F2R2 F1R2 5Kb 3Kb 1.5Kb PCR to check integration of the plasmid/amplicon into the virus genome F1 R1 F2 R2
  19. Viruses produced by homology directed repair (CRISPR) Backbones WT-ASF1033 ASF1033 ΔCD2v 1 gene deletion 1 gene deletion 3 gene deletion 3 gene deletion 6 gene deletion 6 gene deletion Ready for animal experiments
  20. Towards a subunit vaccine for African swine fever
  21. Toward a subunit vaccine • Identification of antigens for use in a subunit vaccine • Screening of peptide library in ELISpot • Production of recombinant viral vectors • Adenovirus/MVA prime-boost • Testing of pools of viral vectors in pigs for protection Adenovirus Vaccinia
  22. Immunisation using attenuated ASF virus ASF1033 ΔCD2v • 10 European breed animals • 10 local breed animals
  23. Clinical scoring/temperature after immunization using attenuated ASF virus ASF1033ΔCD2v
  24. CD2v knockout • The virus is attenuated. • 80-90% of pigs survives 103 HAD. • Clearly, another mutation is needed. • We are soon testing if pigs immunized with ASF1033ΔCD2v are protected against wild-type.
  25. Cellular immune responses after immunization using attenuated ASFΔCD2v 0 200 400 600 800 1000 1200 1400 PB188 PB189 PB190 PB191 PB192 PB195 PB196 PB197 Media ASFV-1033 P72V CD2v Adeno SFU/106PBMC IFN-gamma ELIspot
  26. Antibody responses in pigs after immunization with attenuated ASFΔCD2v 0 20 40 60 80 100 120 0 5 10 15 20 25 30 PB188 PB190 PB191 PB192 PB195 PB196 PB197 Days post infection %inhibition Cut off
  27. Antibody responses in pigs after immunization with attenuated ASFΔCD2v D0D28 D0D28 D0D28 0 50 100 %Blocking Local breed European breed II European breed I
  28. Recognition by PBMC of overlapping peptides spanning the entire proteome immunization with attenuated ASFΔCD2v • 217 gene pools in all • 42 pools recognized in all 3 screenings. • 62 pools not recognized Genepool
  29. Peptide pools recognized in ELISpot using full proteome library immunization with attenuated ASFΔCD2v CD8 cells PBMC
  30. Single antigen recognition by number of animals CD8 cells Best recognition of single Ag: 6/22 animals PBMC Best recognition of single Ag: 17/22 animals
  31. Production of viral vectors with ASF genes • Ten genes from the peptide screen were selected • Each of the 10 genes produced in both adenovirus (HuAd5) and Modified Vaccinia virus Ankara (MVA). • Next, to test pools in the animal model
  32. Virus batch for challenge experiments 0 2 4 6 8 10 0 50 100 Survival - Groups Day after challenge Percentsurvival 102 103 104 105 0 2 4 6 8 38 40 42 Body temperature - Groups Day after challenge Bodytemperature 102 103 104 105 0 2 4 6 8 10 0 5 10 15 Clinical score - Groups Day after challenge Clinicalscore 102 103 104 105 Establishment of minimal lethal challenging dose HAD-titer: 102, 103, 104, 105 5 animals per group Scoring system: King et al.
  33. 33 ILRI Hussein Abkallo Hanneke Hemmink Nicholas Svitek Jeremiah Khayumba Anna Lacasta Elias Awino Rosemary Saya Bernard Odour Emanuel Khazalwa Lucilla Steinaa Collaborators Sanjay Vashee, Assoc prof. J.Craig Venter Instisitute Walter Fuchs, Group leader Friedrich Loeffler Institute Acknowledgements
  34. This presentation is licensed for use under the Creative Commons Attribution 4.0 International Licence. better lives through livestock ilri.org ILRI thanks all donors and organizations which globally support its work through their contributions to the CGIAR Trust Fund
Advertisement